drugset / Trial / NCT00543062
Staccato Prochlorperazine Thorough QT/QTc
RandomizedCrossoverQuadruple-blindTreatment
Summary
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
Timeline
- Start
- 2007-10
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Prochlorperazine | Small molecule | 5 mg | Inhaled |
| Subject | Prochlorperazine | Small molecule | 10 mg | Inhaled |